Literature DB >> 27790307

Primary signet ring cell carcinoma of the prostate treated by radical cystoprostatectomy and chemoradiotherapy.

Sun Wook Kim1, Woohyun Kim1, Yong-Hyun Cho1, Tae-Jung Kim2, Insuk Woo3, Dong Wan Sohn1.   

Abstract

Primary signet ring cell carcinoma (SRCC) of the prostate is very rare. Although SRCC is primarily found in the stomach and colon, it can also be found in the pancreas, breast, thyroid, bladder, and prostate. We recently diagnosed and treated a case of primary SRCC of the prostate. A 56-year-old Korean man was referred to our institution for evaluation of a one-month history of hematuria and recently identified bladder mass. Transurethral resection of the bladder tumour was performed and histological and immunohistochemical evaluation revealed a diagnosis of SRCC with tumour invading into the outer half of the deep muscularis propria. After three weeks, the patient had radical cystoprostatectomy with ileal conduit. Tumour involved both prostate and bladder, but the centre of the tumour was located in the prostate. Duodenoscopy and colon fibroscopy both indicated no evidence of tumour origin in the gastrointestinal (GI) tract. Overall, this tumour was regarded as primary SRCC of the prostate. Concurrent chemoradiotherapy (CCRT) using leucovorin and fluorouracil was initiated two months later. The patient eventually developed bone and liver metastases and died of hepatopathy.

Entities:  

Year:  2016        PMID: 27790307      PMCID: PMC5065415          DOI: 10.5489/cuaj.3122

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  9 in total

1.  A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab.

Authors:  Ana Milena Roldán; Natalia Fernández Núñez; Enrique Grande; Augusto Álvarez García; Luis M Antón-Aparicio
Journal:  Clin Genitourin Cancer       Date:  2012-03-10       Impact factor: 2.872

Review 2.  Primary signet ring cell carcinoma of the prostate.

Authors:  Jonathan N Warner; Leah Y Nakamura; Anna Pacelli; Mitchell R Humphreys; Erik P Castle
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

3.  Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate.

Authors:  Wolfgang Lilleby; Karol Axcrona; G Cecilie Alfsen; Thomas Urnes; Knut H Hole
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

Review 4.  Pathology in prostate research: optimizing the pathological data.

Authors:  Daniel M Berney; Rodolfo Montironi; Lars Egevad
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

Review 5.  Histological variants of prostatic carcinoma and their significance.

Authors:  Peter A Humphrey
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

6.  Mucin-producing carcinoma of the prostate: review of 88 cases.

Authors:  S Saito; H Iwaki
Journal:  Urology       Date:  1999-07       Impact factor: 2.649

7.  Primary signet ring cell carcinoma of the prostate.

Authors:  Whi-An Kwon; Tae Hoon Oh; Sung Hoon Ahn; Jea Whan Lee; Seung Chol Park
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

Review 8.  Primary signet ring cell carcinoma of the prostate: report and review of 42 cases.

Authors:  Kazutoshi Fujita; Hideki Sugao; Takayusu Gotoh; Satoshi Yokomizo; Yasuhiro Itoh
Journal:  Int J Urol       Date:  2004-03       Impact factor: 3.369

Review 9.  Prostatic carcinoma with signet ring cells: a clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature.

Authors:  M Torbenson; R Dhir; A Nangia; M J Becich; S B Kapadia
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

  9 in total
  1 in total

1.  Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate.

Authors:  Qi-Liang Teng; Xin-Rui Yang; Shuang Wen; Zhi-Hong Dai; Hong-Long Wang; Tian-Qing Liu; Liang Wang; Bo Fan; Zhi-Yu Liu
Journal:  Asian J Androl       Date:  2022 Sep-Oct       Impact factor: 3.054

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.